Ms. Shaw, who assumed her role in 2017, will be replaced by the drugmaker’s top executive in Japan, Patrik Jonsson.
The chief of biomedicines role is critical because many of Eli Lilly’s main growth drivers fall under the biomedicine category, including its cancer and migraine prevention drugs.
Eli Lilly also announced its general counsel, Mike Harrington, will retire at the end of the year. The drugmaker is searching for his successor.
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.